Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1850
Peer-review started: May 6, 2021
First decision: June 15, 2021
Revised: July 20, 2021
Accepted: November 15, 2021
Article in press: November 15, 2021
Published online: December 27, 2021
The outbreak of coronavirus disease 2019 (COVID-19) is a global pandemic. Many clinical trials have been performed to investigate potential treatments or vaccines for this disease to reduce the high morbidity and mortality. The drugs of higher interest include umifenovir, bromhexine, remdesivir, lopinavir/ritonavir, steroid, tocilizumab, interferon alpha or beta, ribavirin, fivapiravir, nitazoxanide, ivermectin, molnupiravir, hydroxychloroquine/chloroquine alone or in com
Core Tip: Gastrointestinal symptoms such as anorexia, dyspepsia, nausea, vomiting, diarrhea and abdominal pain are common among patients with coronavirus disease 2019 (COVID-19). Liver injury can be a result of systemic inflammation or cytokine storm, or due to the adverse drug reactions of different treatments. Regular monitoring of liver function is recommended. Patients with inflammatory bowel disease, chronic liver diseases or liver transplant recipients are encouraged to receive the COVID-19 vaccine, and the benefits will outweigh the risks in the vast majority of patients.